带衍生中细胞:对心力衰竭有前途的治疗方法
Ya-Lun Li1,2, En-Guo Chen1, Bing-Bing Ren3
1Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang Province, China.
介酶体 stromal 细胞 (MSCs) 显示出对心力衰竭 (HF) 治疗的前景. 带衍生MSCs (UC-MSCs) 具有优势,但迁移和生存方面的挑战需要进一步研究以获得临床应用.
科学领域:
- 再生医学是一种再生医学.
- 心脏病学 心脏病学
- 干细胞疗法是一种干细胞疗法.
背景情况:
- 心力衰竭 (HF) 是一个主要的全球健康问题,具有显著的发病率和死亡率.
- 中细胞 (MSCs) 正在研究其治疗潜力,以治理高血压.
- 带衍生MSCs (UC-MSCs) 与骨髓衍生MSCs相比具有优势,包括更容易收集,更高的增殖率和降低的免疫性.
更多相关视频
09:05In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells
Published on: August 9, 2017
09:16Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
Published on: February 28, 2018
相关概念视频
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Mesenchymal Stem Cells
Stem Cell Culture
